Skip Therapeutics is developing RNA therapeutics for treatment of rare genetic diseases.
A proprietary computational engine is used to identify disease-causing mutations. Antisense oligonucleotides (ASO) are then developed to modulate splicing in order to generate functional proteins. This approach allows identification of relevant patient cohorts and design of ASOs.
Rare genetic diseases
Prof. Erez Levanon, PhD – Inventor
Prof. Rotem Karni, PhD – Inventor
Ariel Feiglin, PhD – CSO